Clofarabine, Cytarabine and Mitoxantrone (CLAM) for Relapsed or Refractory AML
Status:
Completed
Trial end date:
2018-05-01
Target enrollment:
Participant gender:
Summary
The study aims to evaluate the efficacy of the regimen CLAM in relapsed or refractory AML
when used as first salvage for patients to relapse or fail after standard treatment with
daunorubicin/cytarabine induction.